Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy

Ductal carcinoma in situ (DCIS) often upgrade to invasive breast cancer at surgery. The current study aimed to identify factors associated with pathological underestimation and evaluate concordance rates of biomarkers between biopsy and surgery. Patients diagnosed with DCIS at needle biopsy from 2009 to 2020 were retrospectively reviewed. Univariate and multivariate analyses were performed to identify factors associated with pathological underestimation. Concordance rates between paired biopsy samples and surgical specimens were evaluated. A total of 735 patients with pure DCIS at biopsy were included, and 392 patients (53.3%) underwent pathological underestimation at surgery. Multivariate analysis demonstrated that tumor size > 5.0 cm [odds ratio (OR) 1.79], MRI BI-RADS ≥ 5 categories (OR 2.03), and high nuclear grade (OR 2.01) were significantly associated with pathological underestimation. Concordance rates of ER, PR, HER2 status and Ki-67 between biopsy and surgery were 89.6%, 91.9%, 94.8%, and 76.4% in lesions without pathological underestimation, and were 86.4%, 93.2%, 98.2% and 76.3% for in situ components in lesions with pathological underestimation. Meanwhile, in situ components and invasive components at surgery had concordance rates of 92.9%, 93.8%, 97.4%, and 86.5% for those biomarkers, respectively. In conclusion, lesions diagnosed as DCIS at biopsy have a high rate of pathological underestimation, which was associated with larger tumor size, higher MRI BI-RADS category, and higher nuclear grade. High concordances were found in terms of ER, PR, and HER2 status evaluation between biopsy and surgery, regardless of the pathological underestimation.

• Publication year

  2022

• Venue

  Scientific Reports

• Publication date

  2022-02-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/s41598-022-06206-7PMID 35140303PMCID 8828849
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The 2019 World Health Organization classification of tumours of the breast

  2020cited by this paper
• Does sentinel lymph node biopsy for screening high-grade ductal carcinoma in situ of the breast cause more harm than good?

  2020cited by this paper
• Is it possible to predict underestimation in ductal carcinoma in situ of the breast? Yes, using a simple score!

  2019cited by this paper
• A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast

  2019cited by this paper
• Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes

  2019cited by this paper
• Low-grade screen-detected ductal carcinoma in situ progresses more slowly than high-grade lesions: evidence from an international multi-centre study

  2019cited by this paper
• Ductal carcinoma in situ of breast: update 2019.

  2019cited by this paper
• Ductal Carcinoma In Situ (DCIS) at Breast MRI: Predictors of Upgrade to Invasive Carcinoma.

  2019cited by this paper
• Factors predictive of invasive ductal carcinoma in cases preoperatively diagnosed as ductal carcinoma in situ

  2019cited by this paper
• The prognostic significance of co-existence ductal carcinoma in situ in invasive ductal breast cancer: a large population-based study and a matched case-control analysis.

  2019cited by this paper
• A prediction model for underestimation of invasive breast cancer after a biopsy diagnosis of ductal carcinoma in situ: based on 2892 biopsies and 589 invasive cancers

  2018cited by this paper
• Expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2, and Ki-67 in ductal carcinoma in situ (DCIS) and DCIS with microinvasion

  2018cited by this paper
• Development of a Model to Predict Invasiveness in Ductal Carcinoma In Situ Diagnosed by Percutaneous Biopsy—Original Study and Critical Evaluation of the Literature

  2018cited by this paper
• Estrogen-receptor status and risk of contralateral breast cancer following DCIS

  2018cited by this paper
• Ductal carcinoma in situ diagnosed by breast needle biopsy: Predictors of invasion in the excision specimen.

  2016cited by this paper
• Ductal carcinoma in situ of the breast: Evaluation of main presentations on magnetic resonance imaging compared with findings on mammogram and histology.

  2016cited by this paper
• Ductal carcinoma in situ – update on risk assessment and management

  2016cited by this paper
• Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ.

  2015cited by this paper
• A model to predict upstaging to invasive carcinoma in patients preoperatively diagnosed with ductal carcinoma in situ of the breast

  2015cited by this paper
• Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

  2015cited by this paper
• Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients

  2015cited by this paper
• BI-RADS update.

  2014cited by this paper
• Ductal carcinoma in situ of the breast: can biomarkers improve current management?

  2014cited by this paper
• Features of Occult Invasion in Biopsy‐Proven DCIS at Breast MRI

  2013cited by this paper
• Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer

  2013cited by this paper
• Ductal carcinoma in situ of the breasts: review of MR imaging features.

  2013cited by this paper
• Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.

  2013cited by this paper
• Risk predictors of underestimation and the need for sentinel node biopsy in patients diagnosed with ductal carcinoma in situ by preoperative needle biopsy

  2013cited by this paper
• Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis

  2012cited by this paper
• The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy

  2012cited by this paper
• Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core-needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy.

  2012cited by this paper
• Factors associated with upstaging from ductal carcinoma in situ following core needle biopsy to invasive cancer in subsequent surgical excision.

  2012cited by this paper
• Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer.

  2011cited by this paper
• Discordance in early breast cancer for tumour grade, estrogen receptor, progesteron receptors and human epidermal receptor-2 status between core needle biopsy and surgical excisional primary tumour.

  2011cited by this paper
• Are the Pure In Situ Breast Ductal Carcinomas and Those Associated With Invasive Carcinoma the Same?

  2010cited by this paper
• Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer

  2010cited by this paper
• Predictors of invasive breast cancer in ductal carcinoma in situ initially diagnosed by core biopsy.

  2010cited by this paper
• Comparison of core needle biopsy (CNB) and surgical specimens for accurate preoperative evaluation of ER, PgR and HER2 status of breast cancer patients

  2010cited by this paper
• A Meta-Analysis

  2009cited by this paper
• Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.

  2006cited by this paper
• Wound-induced tumor progression: a probable role in recurrence after tumor resection.

  1998cited by this paper

• Predictors and nomogram for upstaging to invasive breast carcinoma in ductal carcinoma in situ diagnosed by ultrasound-guided core needle biopsy

  2025influential citation
• The prognostic and predictive role of class III β-Tubulin and hENT1 expression in patients with advanced pancreatic ductal adenocarcinoma.

  2024cites this paper
• Adding contrast-enhanced ultrasound can improve the predictive ability of breast conventional ultrasound and mammography for pathological upgrade of biopsy-confirmed ductal carcinoma in situ.

  2024cites this paper
• Prospective validation of 18F-Fluoroethylcholine as a tracer in PET/MRI for the evaluation of breast lesions and prediction of lymph node status

  2023cites this paper